A Study of Intravesical Bacillus Calmette-Guerin (BCG) in combination with ALT-803 in Patients with Non-Muscle Invasive Bladder Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-muscle Invasive Bladder Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have non-muscle invasive bladder cancer of the transitional cell carcinoma high-grade subtype who have CIS or high grade papillary disease. 2) Patients are eligible if the diagnostic biopsy was done within 3 months of treatment start and a cystoscopy to show that no tumor removal was done within 6 weeks of treatment start. 3) Patients are eligible for intravesical BCG therapy and patients have no clinical sign of severe pulmonary dysfunction.

You may not be eligible for this study if the following are true:

  • 1) Patients have prior BCG treatment or known hypersensitivity to BCG. Patients who have received more than a single-dose post-operative treatment of mitomycin-C or gemcitabine are excluded. 2) Patients currently receiving other anticancer therapies. 3) Patients have history of muscle-invasive, locally advanced, metastatic and/or extravesical bladder cancer or any other cancer within the past 5 years. 4) Patients are undergoing chronic systematic steroid therapy.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.